Reviewer's report

Title: Microarray Analysis Reveals Genetic Pathways Modulated by Tipifarnib in Acute Myeloid Leukemia

Version: 2 Date: 22 August 2004

Reviewer: Jason Gotlib

Reviewer's report:

General

Mitch Raponi and colleagues have adequately addressed my comments, with substantive changes made in the manuscript to reflect this. I recommend publication.

-------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

None

-------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

None

-------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

The authors may choose to specifically comment that RT-PCR for kras will be analyzed from the phase II clinical trial samples to validate the current findings.

What next?: Accept after discretionary revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

None